Neil Solomons, M.D.
Expert Advisor – Rare Disease
Dr. Neil Solomons co-founded Aurinia Pharmaceuticals in 2012, where he was Chief Medical Officer. He is a pharmaceutical physician with 25 years of clinical development and medical affairs experience in both large pharma and biotech. He is a recognized expert in rare disease drug development and is widely published in this field, gaining FDA and EMA approval for Lupkynis® in active lupus nephritis.
Prior to founding Aurinia, Dr. Solomons was at Vifor Pharma, formerly Aspreva Pharmaceuticals where he held the position of Vice President, Research and Development. He was the lead clinician in the development of CellCept® in rare diseases, and led clinical development teams of over 50 people that saw the completion, reporting, and publication of studies in pemphigus vulgaris and myasthenia gravis (both industry firsts) and the successful landmark lupus nephritis study called the Aspreva Lupus Management Study (ALMS). He was responsible for all clinical development activities from Phases 1 to 3, and participated in the formulation of R&D strategy, portfolio management, and due diligence efforts.
Dr. Solomons has held a variety of positions at Roche in both global clinical development and medical affairs in transplantation, virology, and auto-immune diseases. While at Roche, he led a diverse team in the development and implementation of post-marketing studies for its transplantation (CellCept® and Zenapax®) and virology (Cytovene®) franchises.
After receiving his MBBS (M.D.) at Guy’s Hospital Medical School, London in 1991, Dr. Solomons subsequently worked as a physician in London UK, completing specialist training in anesthesia and intensive care. His research interests included sepsis and chronic pain.